Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly

ConclusionsPegV and SRLs had comparable effects on VF risk in acromegaly. The activity of disease was the main determinant of VFs independently of the drug used to control acromegaly.
Source: Pituitary - Category: Endocrinology Source Type: research